Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harpoon Therapeutics Inc (NQ: HARP )

10.00 -0.03 (-0.30%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 124,662
Open 10.11
Bid (Size) 10.00 (1)
Ask (Size) 10.69 (2)
Prev. Close 10.03
Today's Range 9.800 - 10.71
52wk Range 3.110 - 33.55
Shares Outstanding 37,595,787
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Harpoon Therapeutics Inc.
Via GlobeNewswire

Performance

YTD
+40.85%
+40.85%
1 Month
+61.29%
+61.29%
3 Month
+25.16%
+25.16%
6 Month
+34.39%
+34.39%
1 Year
+41.32%
+41.32%

More News

Read More
Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Why Biophytis Shares Are Trading Higher By Over 12%: Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Why Logitech International Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Via Benzinga
What's Going On With Harpoon Therapeutics Stock Monday?
Via Benzinga
Why Troika Media Group Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why EngageSmart Shares Are Trading Higher By Around 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Harpoon Therapeutics Announces Up to $150 Million Private Placement
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Harpoon Therapeutics Inc. (NASDAQ: HARP) Leading the Way in Wednesday Trading Based on Percentage Gain
Via Investor Brand Network
Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Presents HPN217 Interim Phase 1 Data at the IMS Annual Meeting
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort
From Harpoon Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Clearmind Medicine Shares Are Trading Lower By 53%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Why Is Immuno-Oncology Firm Harpoon Therapeutics Stock Trading Lower Today?
Via Benzinga
Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Harpoon Therapeutics Abstract for HPN217 Accepted for Poster Presentation at the 20th International Myeloma Society Annual Meeting
From Harpoon Therapeutics Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.